Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 5/20 | 0.63 |
| ▸ | EGFR | P00533 | 3/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357662 | 0.94 | ERBB2 (0.61) | ERBB2EGFRLRRK2IGF1RPLK4 | |
| SCHEMBL5367950 | 0.93 | ERBB2 (0.74) | ERBB2EGFRLRRK2IGF1RPLK4 | |
| SCHEMBL5377234 | 0.93 | ERBB2 (0.58) | ERBB2EGFRLRRK2IGF1RPLK4 | |
| SCHEMBL5361294 | 0.90 | ERBB2 (0.54) | ERBB2EGFRLRRK2IGF1RPLK4 | |
| SCHEMBL5364127 | 0.88 | ERBB2 (0.73) | ERBB2EGFRLRRK2IGF1RPLK4 | |
| SCHEMBL5362863 | 0.87 | ERBB2 (0.65) | ERBB2EGFRLRRK2IGF1RPLK4 | |
| SCHEMBL5358637 | 0.87 | ERBB2 (0.51) | ERBB2EGFRLRRK2IGF1RPSEN1 | |
| SCHEMBL5366802 | 0.86 | LRRK2 (0.70) | ERBB2EGFRLRRK2PLK4GSK3B | |
| SCHEMBL5368833 | 0.86 | PLK4 (0.60) | ERBB2EGFRLRRK2PLK4GSK3B | |
| SCHEMBL5376624 | 0.84 | ERBB2 (0.50) | ERBB2EGFRLRRK2IGF1RPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | ERBB2 19/4885EGFR 286/4885LRRK2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.